Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 29Ovarian Neoplasms 27Breast Neoplasms 27Lung Neoplasms 26Carcinoma, Ovarian Epithelial 20Fallopian Tube Neoplasms 15Adenocarcinoma of Lung 14Head and Neck Neoplasms 13Brenner Tumor 11Uterine Cervical Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Urinary Bladder Neoplasms 9Esophageal Neoplasms 9Stomach Neoplasms 8Endometrial Neoplasms 8Urethral Neoplasms 7Adenocarcinoma, Bronchiolo-Alveolar 6Sarcoma 5Prostatic Neoplasms 5Adenocarcinoma Of Esophagus 5Neurotoxicity Syndromes 4Neoplasm Metastasis 4Testicular Neoplasms 3Salivary Gland Neoplasms 3Radiation Injuries 3Esophageal Squamous Cell Carcinoma 3Breast Neoplasms, Male 3Thymoma 2Testicular Germ Cell Tumor 2Small Cell Lung Carcinoma 2

Interventions

pegfilgrastim 1Taxes 1Platinum 1Paclitaxel 1Granulocyte Colony-Stimulating Factor 1Fulvestrant 1Filgrastim 1Doxorubicin 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Recurrent Uterine Corpus Carcinoma × Paclitaxel × Clear all
NCT00063999 2021-10-19

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

GOG Foundation

Phase 3 Completed
1,381 enrolled 12 charts
Gynecologic

Recurrent Uterine Corpus Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡